This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


4o13

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (12:36, 1 March 2024) (edit) (undo)
 
(2 intermediate revisions not shown.)
Line 1: Line 1:
==The crystal structure of NAMPT in complex with GNE-618==
==The crystal structure of NAMPT in complex with GNE-618==
-
<StructureSection load='4o13' size='340' side='right' caption='[[4o13]], [[Resolution|resolution]] 1.75&Aring;' scene=''>
+
<StructureSection load='4o13' size='340' side='right'caption='[[4o13]], [[Resolution|resolution]] 1.75&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>[[4o13]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4O13 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4O13 FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[4o13]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4O13 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4O13 FirstGlance]. <br>
-
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=2P1:N-(4-{[3-(TRIFLUOROMETHYL)PHENYL]SULFONYL}BENZYL)-2H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXAMIDE'>2P1</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.75&#8491;</td></tr>
-
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4o14|4o14]], [[4o15|4o15]], [[4o16|4o16]], [[4o17|4o17]], [[4o18|4o18]], [[4o19|4o19]], [[4o1a|4o1a]], [[4o1b|4o1b]], [[4o1c|4o1c]], [[4o1d|4o1d]], [[4o28|4o28]]</td></tr>
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2P1:N-(4-{[3-(TRIFLUOROMETHYL)PHENYL]SULFONYL}BENZYL)-2H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXAMIDE'>2P1</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr>
-
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Nicotinamide_phosphoribosyltransferase Nicotinamide phosphoribosyltransferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.4.2.12 2.4.2.12] </span></td></tr>
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4o13 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4o13 OCA], [https://pdbe.org/4o13 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4o13 RCSB], [https://www.ebi.ac.uk/pdbsum/4o13 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4o13 ProSAT]</span></td></tr>
-
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4o13 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4o13 OCA], [http://pdbe.org/4o13 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4o13 RCSB], [http://www.ebi.ac.uk/pdbsum/4o13 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4o13 ProSAT]</span></td></tr>
+
</table>
</table>
== Function ==
== Function ==
-
[[http://www.uniprot.org/uniprot/NAMPT_HUMAN NAMPT_HUMAN]] Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway (By similarity).
+
[https://www.uniprot.org/uniprot/NAMPT_HUMAN NAMPT_HUMAN] Catalyzes the condensation of nicotinamide with 5-phosphoribosyl-1-pyrophosphate to yield nicotinamide mononucleotide, an intermediate in the biosynthesis of NAD. It is the rate limiting component in the mammalian NAD biosynthesis pathway (By similarity).
-
<div style="background-color:#fffaf0;">
+
-
== Publication Abstract from PubMed ==
+
-
Inhibiting NAD biosynthesis by blocking the function of nicotinamide phosphoribosyl transferase (NAMPT) is an attractive therapeutic strategy for targeting tumor metabolism. However, the development of drug resistance commonly limits the efficacy of cancer therapeutics. This study identifies mutations in NAMPT that confer resistance to a novel NAMPT inhibitor, GNE-618, in cell culture and in vivo, thus demonstrating that the cytotoxicity of GNE-618 is on target. We determine the crystal structures of six NAMPT mutants in the apo form and in complex with various inhibitors and use cellular, biochemical and structural data to elucidate two resistance mechanisms. One is the surprising finding of allosteric modulation by mutation of residue Ser165, resulting in unwinding of an alpha-helix that binds the NAMPT substrate 5-phosphoribosyl-1-pyrophosphate (PRPP). The other mechanism is orthosteric blocking of inhibitor binding by mutations of Gly217. Furthermore, by evaluating a panel of diverse small molecule inhibitors, we unravel inhibitor structure activity relationships on the mutant enzymes. These results provide valuable insights into the design of next generation NAMPT inhibitors that offer improved therapeutic potential by evading certain mechanisms of resistance.
+
-
 
+
-
Structural Basis for Resistance to Diverse Classes of NAMPT Inhibitors.,Wang W, Elkins K, Oh A, Ho YC, Wu J, Li H, Xiao Y, Kwong M, Coons M, Brillantes B, Cheng E, Crocker L, Dragovich PS, Sampath D, Zheng X, Bair KW, O'Brien T, Belmont LD PLoS One. 2014 Oct 6;9(10):e109366. doi: 10.1371/journal.pone.0109366., eCollection 2014. PMID:25285661<ref>PMID:25285661</ref>
+
-
 
+
-
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+
-
</div>
+
-
<div class="pdbe-citations 4o13" style="background-color:#fffaf0;"></div>
+
==See Also==
==See Also==
-
*[[Phosphoribosyltransferase|Phosphoribosyltransferase]]
+
*[[Phosphoribosyltransferase 3D structures|Phosphoribosyltransferase 3D structures]]
-
== References ==
+
-
<references/>
+
__TOC__
__TOC__
</StructureSection>
</StructureSection>
-
[[Category: Nicotinamide phosphoribosyltransferase]]
+
[[Category: Homo sapiens]]
-
[[Category: Brillantes, B]]
+
[[Category: Large Structures]]
-
[[Category: Coons, M]]
+
[[Category: Brillantes B]]
-
[[Category: Oh, A]]
+
[[Category: Coons M]]
-
[[Category: Wang, W]]
+
[[Category: Oh A]]
-
[[Category: Transferase-transferase inhibitor complex]]
+
[[Category: Wang W]]

Current revision

The crystal structure of NAMPT in complex with GNE-618

PDB ID 4o13

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/4o13"
Personal tools